First Person Dosed in Novel Gene Editing Clinical TrialVerve Therapeutics announced today (July 12) that it has dosed the first participant in a clinical trial assessing the safety and…Sep 18, 2022Sep 18, 2022
How Patient-Centered Strategies Are Transforming Clinical TrialsSeptember 2, 2022 | Patient centricity is a term on everyone’s lips right now, and with good reason. The life science sector is coming…Sep 11, 2022Sep 11, 2022
A Blended Solution-How Midsize Pharmaceutical and Biotech Companies Can Optimize the Delivery of…August 12, 2022 | Traditionally, biopharma companies use two outsourcing models to deliver their clinical trial portfolios. First, the…Sep 4, 2022Sep 4, 2022
Study shows encouraging therapeutic options for patients with relapsed multiple myelomaMount Sinai researchers have published results that show encouraging therapeutic options for patients with the blood cancer multiple…Sep 1, 2022Sep 1, 2022
CSL reports Phase III data for garadacimab to treat hereditary angioedemaCSL has reported positive top-line data from the Phase III VANGUARD clinical trial of garadacimab (CSL312) as a durable preventive therapy…Aug 18, 2022Aug 18, 2022
CSL reports Phase III data for garadacimab to treat hereditary angioedemaCSL has reported positive top-line data from the Phase III VANGUARD clinical trial of garadacimab (CSL312) as a durable preventive therapy…Aug 18, 2022Aug 18, 2022
Tufts Study Provides ‘First Hard Metrics’ Around Decentralized Clinical TrialsThe economic savings, as revealed by a newly completed Tufts CSDD study, come from reduced cycle times, improved patient screening and…Jul 31, 2022Jul 31, 2022
Yuyu Pharma begins subject enrolment in Phase II dry eye disease studyYuyu Pharma has enrolled the first participant in a Phase II clinical study of YP-P10 Ophthalmic Solution to treat dry eye disease (DED).Jul 21, 2022Jul 21, 2022
Cardurion begins subject dosing in Phase II heart failure trialCardurion Pharmaceuticals has started dosing of subjects in CARDINAL-HF, a Phase II clinical trial of its phosphodiesterase-9 (PDE9)…Jul 20, 2022Jul 20, 2022
Capricor doses first subject in Phase III Duchenne muscular dystrophy trialCapricor Therapeutics has dosed the first subject in the Phase III HOPE-3 clinical trial of cell therapy, CAP-1002, to treat late-stage…Jul 20, 2022Jul 20, 2022
